Unveiling the Metabolic Effects of Ganoderma lucidum in Humans: A Systematic Review and Meta-Analysis
,
Abstract
Ganoderma is a mushroom renowned for its medical attributes, encompassing hepatoprotective, hypocholesterolemic, antioxidant, anti-inflammatory, hypoglycemic, and immunomodulatory activities. This study aimed to evaluate the effect of Ganoderma lucidum supplementation on metabolic profile in adult populations. Articles were retrieved from MEDLINE, ScienceDirect, ProQuest, and Google Scholar databases until the year 2023. Inclusion criteria were all published trials examining the effect of G. lucidum supplementation on metabolic profile in adult populations. The quality assessment and meta-analysis was performed. A total of 13 studies (two in populations with metabolic syndrome, two in type 2 diabetes mellitus, one in fibromyalgia patients, six in healthy populations, and two patients with coronary arterial disease) were included in this study, and seven studies met the eligibility criteria for meta-analysis. G. lucidum was mostly administered as capsules. There were no significant differences among outcomes in between group comparisons of high-density lipoprotein, low-density lipoprotein, total cholesterol, and fasting plasma glucose in the metabolic syndrome population (p value=1.00, 0.90, 0.78, and 0.33, respectively). Within group comparisons among the healthy population, only serum glutamic-pyruvic transaminase (p=0.03) and total cholesterol (p<0.0001) exhibited significant changes. In conclusion, we observed significant reductions in serum glutamic pyruvic transaminase and total cholesterol levels among healthy individuals following G. lucidum supplementation. However, despite promising preliminary findings, greater sample numbers with a more diverse demographic studies are required to fully understand and uncover any capabilities of G. lucidum in a therapeutic role.
Oke MA, Afolabi FJ, Oyeleke OO, Kilani TA, Adeosun AR, et al. Ganoderma lucidum: Unutilized natural medicine and promising future solution to emerging diseases in Africa. Front Pharmacol [Internet]. 2022;13:952027
El Sheikha AF. Nutritional profile and health benefits of Ganoderma lucidum “Lingzhi, Reishi, or Mannentake” as functional foods: current scenario and future perspectives. Foods 2022;11:1030.
Park HJ. Current uses of mushrooms in cancer treatment and their anticancer mechanisms. Int J Mol Sci 2022;23:10502.
Takahara M, Katakami N, Hayashino Y, Nishimura R, Suzuki H, et al. Different impacts of metabolic profiles on future risk of cardiovascular disease between diabetes with and without established cardiovascular disease: the Japan diabetes complication and its prevention prospective study 7 (JDCP study 7). Acta Diabetol 2022;59:57-65.
Swarup S, Goyal A, Grigorova Y, Zeltser R. Metabolic Syndrome. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 [cited 2024 Jan 11]. Available from: http://www.ncbi.nlm.nih.gov/books/NBK459248/
Heeren J, Scheja L. Metabolic-associated fatty liver disease and lipoprotein metabolism. Mol Metab 2021;50:101238.
Boh B, Berovic M, Zhang J, Zhi-Bin L. Ganoderma lucidum and its pharmaceutically active compounds. Biotechnol Annu Rev 2007;13:265-301.
Aref M, Khoshhali M, Ghasemi P, Adeli S, Heidari-Beni M, et al. Effect of Ganoderma lucidum on serum lipid profiles: A systematic review and meta-analysis on animal studies. J Res Med Sci 2023;28:70.
Klupp NL, Chang D, Hawke F, Kiat H, Cao H, et al. Ganoderma lucidum mushroom for the treatment of cardiovascular risk factors. Cochrane Database Syst Rev 2015;2015:CD007259.
Chan SW, Tomlinson B, Chan P, Lam CWK. The beneficial effects of Ganoderma lucidum on cardiovascular and metabolic disease risk. Pharm Biol 2021;59:1159-1169.
Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. Syst Rev 2021;10:89.
Wan X, Wang W, Liu J, Tong T. Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range. BMC Med Res Methodol 2014;14:135.
Luo D, Wan X, Liu J, Tong T. Optimally estimating the sample mean from the sample size, median, mid-range, and/or mid-quartile range. Stat Methods Med Res 2018;27:1785-1805.
Sterne JAC, Savović J, Page MJ, Elbers RG, Blencowe NS, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ 2019;366:l4898.
Kolaski K, Logan LR, Ioannidis JPA. Guidance to best tools and practices for systematic reviews. Jbi Evid Synth 2023;21:1699.
Tantry TP, Karanth H, Shetty PK, Kadam D. Self-learning software tools for data analysis in meta-analysis. Korean J Anesthesiol 2021;74:459-461.
Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327:557.
Gao Y, Lan J, Dai X, Ye J, Zhou S. A Phase I/II Study of Ling Zhi Mushroom Ganoderma lucidum (W.Curt.:Fr.)Lloyd (Aphyllophoromycetideae) extract in patients with type ii diabetes mellitus. Int J Med Mushrooms 2004;6:.
Gao Y, Chen G, Dai X, Ye J, Zhou S. A Phase I/II Study of Ling Zhi Mushroom Ganoderma lucidum (W.Curt.:Fr.) Lloyd (Aphyllophoromycetideae) Extract in Patients with Coronary Heart Disease. Int J Med Mushrooms 2004;6.
Wang CW, Tschen JSM, Sheu WHH. Ganoderma lucidum on metabolic control in type 2 diabetes subjects - A double blinded placebo control study. J Intern Med Taiwan 2008;19:54-60.
Chu TTW, Benzie IFF, Lam CWK, Fok BSP, Lee KKC, et al. Study of potential cardioprotective effects of Ganoderma lucidum (Lingzhi): results of a controlled human intervention trial. Br J Nutr 2012;107:1017-1027.
Klupp NL, Kiat H, Bensoussan A, Steiner GZ, Chang DH. A double-blind, randomised, placebo-controlled trial of Ganoderma lucidum for the treatment of cardiovascular risk factors of metabolic syndrome. Sci Rep 2016;6:29540.
Sargowo D, Purwanto EF, Nugroho FW, Kamila PA, Irawan D, et al. The role of polysaccharide peptides of miselia Ganoderma lucidum extracts on IL-1, IL-6, HSCRP and no in dislipidemic patients with or without hypertension in STEMI and NSTEMI patients. AIP Conf Proc 2019;2108:020027.
Babamiri S, Mojani Qomi MS, Shiehmorteza M. The Efficacy of Ganoderma lucidum in Overweight Individuals: A Randomized Placebo-controlled trial. Mediterr J Nutr Metab 2022;15:263-271.
Wachtel-Galor S, Szeto YT, Tomlinson B, Benzie IFF. Ganoderma lucidum ('Lingzhi’); acute and short-term biomarker response to supplementation. Int J Food Sci Nutr 2004;55:75-83.
Wachtel-Galor S, Tomlinson B, Benzie IFF. Ganoderma lucidum (“Lingzhi”), a Chinese medicinal mushroom: biomarker responses in a controlled human supplementation study. Br J Nutr 2004;91:263-269.
Chiu HF, Fu HY, Lu YY, Han YC, Shen YC, et al. Triterpenoids and polysaccharide peptides-enriched Ganoderma lucidum: a randomized, double-blind placebo-controlled crossover study of its antioxidation and hepatoprotective efficacy in healthy volunteers. Pharm Biol 2017;55:1041-1046.
Wu Q, Zhang H, Wang PG, Chen M. Evaluation of the efficacy and safety of Ganoderma lucidum mycelium-fermented liquid on gut microbiota and its impact on cardiovascular risk factors in human. RSC Adv 2017;7:45093-45100.
Sarikaphuti A, Napavichayanun S, Thaipitakwong T, Roskhrua P, Aramwit P. Longan syrup with lingzhi mushroom extract: Evaluation of safety and efficacy on immune and inflammatory modulation in healthy adults. Agric Nat Resour 2021;55:579-588.
Pazzi F, Adsuar JC, Domínguez-Muñoz FJ, García-Gordillo MÁ, Gusi N, et al. Effects of Ganoderma lucidum and Ceratonia siliqua on blood glucose, lipid profile, and body composition in women with fibromyalgia. Nutr Hosp 2021;38:139-145.
Teekachunhatean S, Sadja S, Ampasavate C, Chiranthanut N, Rojanasthien N, et al. Pharmacokinetics of ganoderic acids A and F after oral administration of Ling Zhi Preparation in healthy male volunteers. Evid-Based Complement Altern Med 2012;2012:780892.
Wachtel-Galor S, Yuen J, Buswell JA, Benzie IFF. Ganoderma lucidum (Lingzhi or Reishi): A Medicinal Mushroom. In: Benzie IFF, Wachtel-Galor S, editors. Herbal Medicine: Biomolecular and Clinical Aspects [Internet]. 2nd ed. Boca Raton (FL): CRC Press/Taylor & Francis; 2011 [cited 2024 Jan 11]. Available from: http://www.ncbi.nlm.nih.gov/books/NBK92757/
Gao Y, Zhou S, Jiang W, Huang M, Dai X. Effects of ganopoly (a Ganoderma lucidum polysaccharide extract) on the immune functions in advanced-stage cancer patients. Immunol Invest 2003;32:201-215.
Sarker MMR. Antihyperglycemic, insulin-sensitivity and anti-hyperlipidemic potential of Ganoderma lucidum, a dietary mushroom, on alloxan- and glucocorticoid-induced diabetic Long-Evans rats. Funct Foods Health Dis 2015;5:450.
Lim CY, In J. Considerations for crossover design in clinical study. Korean J Anesthesiol 2021;74:293-299.
Li Y, Talbot CL, Chandravanshi B, Ksiazek A, Sood A, et al. Cordyceps inhibits ceramide biosynthesis and improves insulin resistance and hepatic steatosis. Sci Rep 2022;12:7273.
Cao C, Yang S, Zhou Z. The potential application of Cordyceps in metabolic-related disorders. Phytother Res 2020;34:295-305.
Mohamad Ansor N, Abdullah N, Aminudin N. Anti-angiotensin converting enzyme (ACE) proteins from mycelia of Ganoderma lucidum (Curtis) P. Karst. BMC Complement Altern Med 2013;13:256.
Wu Q, Li Y, Peng K, Wang XL, Ding Z, et al. Isolation and characterization of three antihypertension peptides from the mycelia of Ganoderma Lucidum (Agaricomycetes). J Agric Food Chem 2019;67:8149-8159.
Farský Š, Strišková A, Borčin M. Hypertension treatment in patients with metabolic syndrome and/or type 2 diabetes mellitus: analysis of the therapy effectivity and the therapeutic inertia in outpatient study. Cardiol Res Pract 2018;2018:e8387613.
Hijikata Y, Yamada S. Effect of Ganoderma lucidum on postherpetic neuralgia. Am J Chin Med 1998;26:375-381.
Zhang Q, Zuo F, Nakamura N, Ma CM, Hattori M. Metabolism and pharmacokinetics in rats of ganoderiol F, a highly cytotoxic and antitumor triterpene from Ganoderma lucidum. J Nat Med 2009;63:304-310.
Berger A, Rein D, Kratky E, Monnard I, Hajjaj H, et al. Cholesterol-lowering properties of Ganoderma lucidum in vitro, ex vivo, and in hamsters and minipigs. Lipids Health Dis 2004;3:2.
Ahmad MF, Ahmad FA, Zeyaullah Md, Alsayegh AA, Mahmood SE, et al. Ganoderma lucidum: novel insight into hepatoprotective potential with mechanisms of action. Nutrients 2023;15:1874.
Zhong D, Xie Z, Huang B, Zhu S, Wang G, et al. Ganoderma Lucidum polysaccharide peptide alleviates hepatoteatosis via modulating bile acid metabolism dependent on FXR-SHP/FGF. Cell Physiol Biochem 2018;49:1163-1179.
Susilo RJK, Winarni D, Husen SA, Hayaza S, Punnapayak H, et al. Hepatoprotective effect of crude polysaccharides extracted from Ganoderma lucidum against carbon tetrachloride-induced liver injury in mice. Vet World 2019;12:1987-1991.
| Files | ||
| Issue | Vol 9, No 3, 2024 | |
| Section | Review Article(s) | |
| DOI | https://doi.org/10.18502/tim.v9i3.16536 | |
| Keywords | ||
| Ganoderma lucidum Lingzhi Reishi Metabolic profiles | ||
| Rights and permissions | |
|
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
